Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04041427
Other study ID # ABZ0201
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 17, 2019
Est. completion date February 28, 2020

Study information

Verified date May 2021
Source Universidad Nacional de Salta
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project will develop and assess the feasibility and acceptability of a urine-based assay to monitor adherence to Mass Drug Administration (MDA) campaigns within Soil-transmitted helminthiasis (STH) control programs, evaluating the urine and serum pharmacokinetics of ALBENDAZOLE (ABZ) and its metabolites across a variety of food/fast conditions, age, gender and body weight. The final goal is to obtain a field ready tool for the measurement of adherence to anthelmintic treatment at a community level that serves as a coverage/adherence indicator and a reference standard for other monitoring tools.


Description:

Soil-Transmitted-Helminthic (STH) infections are a major public health issue affecting the world's poorest populations. Control strategies for STH have been focused on the use of mass chemotherapy often delivered to school-aged-children; although there is strong interest in considering community wide MDA to achieve transmission interruption of STH. In these programs, directly observed treatment is not consistently or frequently achieved and so the verification of reported adherence is crucial to understanding of the impact of these programs. It is important to differentiate a lack of adherence to treatment with albendazole (ABZ) from absorption/metabolism/resistance-related therapeutic failures. In that context, tools to evaluate, by means of non-invasive measures, treatment adherence either in adults or children, should be developed. In addition, drug absorption and metabolism among people may vary enormously depending on different factors such as genetics, age, gender, diet, weight and disease. Any of those factors may alter the ABZ/metabolites disposition kinetics and, consequently, the exposure of the target STH to the active drug. The current research project proposes to establish evidence for the feasibility and usability of such a tool within MDA programs from the perspectives of the end-user (community), implementing partners, National Neglected Tropical Diseases (NTD) program and the World Health Organization. The proposed use case for this currently developed assay is to confirm the findings of the standard coverage survey (based on self-report) in the context of community MDA. Further validation and technical development of a field ready tool for monitoring adherence to albendazole, in addition to the identification of key factors affecting drug therapeutic response is proposed within this project. Main goals of the current proposal: 1. To assess key factors affecting the feasibility of using a urinary assay to monitor adherence to MDA within STH control programs, including tool acceptability, tool learnability, system capacity to deliver, timing of administration, frequency of administration, adequate breadth of administration, sustainability of use, responsiveness of health systems to tool output, and efficiency of administration. 2. To evaluate the influence of diet, fasting, age, gender and body weight on the serum disposition kinetics and pattern of urinary excretion of ABZ/metabolites in non-infected human volunteers. 3. To evaluate the relationship between drug serum/urine concentrations with potential factors affecting ABZ/metabolites disposition kinetics in children. 4. To characterize the pattern of amino-ABZSO2 urinary excretion in non-infected human volunteers treated with ABZ and to determine the longest period of time after ABZ treatment where amino-ABZSO2 can be measured in urine (alternatively to ABZSO) as an indirect assessment of an individual's adherence to treatment. 5. To determine drug/metabolites chemical stability in urine samples at different temperatures (reproducing environmental conditions of tropical weather). Study procedures: Twelve (12) healthy adult volunteers (body weight between 45 and 75 kg, women n=6 and men n=6) will participate in a crossover design with three (3) different experimental phases. In Phase I, volunteers will be assigned to either Group I, Group II or Group III (n=4 each, two female and two male individuals). In the following 2 Phases of the study, volunteers will be cross-over between the other 2 Groups, with a 14-day washout period between Phases. All groups and phases will receive 400 mg of ABZ (Glaxo SmithKline). Group I (heavy meal):30 minutes after a high-fatty meal (estimated fat content 40 g). Group II (light meal):30 minutes after a light meal (infusion tea). Group III (fasted):at 8-hours fasting condition. Prior to ABZ treatment (sampling time =0), a baseline blood (5 mL) and urine (10 mL) samples will be obtained in each phase. Venous blood samples will be collected at 2, 4, 8, 12, 24, 36, 48 and 72 h, after ABZ administration. Urine samples will be collected at 2, 4, 8, 12, 24, 36, 48 and 72 h post-treatment. Samples will be stored at -20ºC until HPLC analysis of ABZ/metabolites. Urine samples from time 4-hours will be aliquoted in 3 in order to evaluate the effect of storage at 32°C (in an incubator) for 12 and 24 hours before freezing at -20°C in the measurement of drug/metabolite levels. A total of 12 samples from Group 1 will be included in this sub-sample analysis which will provide information on the stability of the samples at temperatures in tropical environments.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date February 28, 2020
Est. primary completion date September 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Body Mass Index: 18 to 25. - Physical exam without significant abnormal findings Exclusion Criteria: - Pregnancy - Lactation - Use of ABZ or other benzimidazole drugs in the previous 30 days. - History of intolerance to ABZ. - Malabsorption and/or other gastrointestinal conditions that might compromise ABZ absorption.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Albendazole Pill
Albendazole 400mg po
Other:
High fat content diet
High fat content diet
Moderate fat content die
Moderate fat content die

Locations

Country Name City State
Argentina Instituto de Investigaciones de Enfermedades Tropicales, UNSalta Oran Salta

Sponsors (4)

Lead Sponsor Collaborator
Universidad Nacional de Salta CIVETAN-Tandil, UNCPBA, Fundacion Mundo Sano, Natural History Museum, London, UK

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urine albendazole levels Albendazole and its metabolites will be measured in urine samples through high performance liquid chromatography (HPLC). 96 hours
Primary Serum albendazole levels Albendazole and its metabolites will be measured in serum samples obtained from venous blood through HPLC. 72 hours
See also
  Status Clinical Trial Phase
Completed NCT04041453 - Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients Phase 2
Active, not recruiting NCT03014167 - Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Phase 3
Completed NCT02385058 - Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Phase 4
Withdrawn NCT02636803 - Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Phase 2
Completed NCT02725255 - Design and Clinical Evaluation of a School Meal With Deworming Properties Phase 2/Phase 3
Active, not recruiting NCT04227834 - Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education N/A
Completed NCT03173742 - Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) Phase 1
Completed NCT02397772 - Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya Phase 4
Completed NCT00130910 - Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation N/A
Completed NCT00004996 - Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections
Recruiting NCT00001230 - Host Response to Infection and Treatment in Filarial Diseases
Completed NCT02396407 - Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health N/A
Terminated NCT01271049 - An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths N/A
Terminated NCT00817713 - Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa? N/A
Completed NCT02362932 - The Effect of an Urban Sanitation Intervention on Child Health N/A
Completed NCT02420574 - Assessment of Drug Efficacy of Local Albendazole N/A
Completed NCT00507221 - Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression N/A
Completed NCT00469495 - Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis N/A
Recruiting NCT01459146 - Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Phase 4
Recruiting NCT01308268 - Management of Soil-transmitted Helminthiasis and Strongyloidiasis N/A